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Abstract 
Review on t(1;17)(p36;q21) SPOP/PRDM16 
translocation in astrocytic tumor, with data on the 
genes involved. 
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Clinics and pathology 
Disease 
A t(1;17)(p36;q21) was found in a case of 
astrocytoma grade I-II, but no further data is 
available (Yoshihara et al 2015). 
Clinics 
Grade I astrocytomas are pilocytic astrocytoma and 
subependymal giant cell astrocytoma, the latter 
being the most common central nervous system 
neoplasm in  tuberous sclerosis; they are slow 
growing tumors; they typically occur during the 
first two decades of life. Grade II astrocytomas are 
pilomyxoid astrocytoma occurring most often in 
infants and very young children, diffuse 
astrocytoma, seen at any age, but often between 
ages 30-40, and  pleomorphic xanthoastrocytoma,  
typically developing in children and young adults. 
Genes involved and 
proteins 
PRDM16 (PR domain containing 16) 
Location 
1p36.32 
DNA / RNA 
11 splice variants 
Protein 
1276 amino acids and smaller proteins. Contains a 
N-term PR domain; 7 Zinc fingers, a proline-rich 
domain, and 3 Zinc fingers in the C-term. Binds 
DNA.  
Transcription activator; PRDM16 has an intrinsic 
histone methyltransferase activity. PRDM16 forms 
a transcriptional complex with CEBPB. PRDM16 
plays a downstream regulatory role in mediating 
TGFB signaling (Bjork et al., 2010).  
PRDM16 induces brown fat determination and 
differentiation. PRDM16 is expressed selectively in 
the earliest stem and progenitor hematopoietic cells, 
and is required for the maintenance of the 
hematopoietic stem cell pool during development. 
PRDM16 is also required for survival, cell-cycle 
regulation and self-renewal in neural stem cells 
(Chuikov et al., 2010; Kajimura et al., 2010; Aguilo 
et al., 2011; Chi and Cohen, 2016). 




DNA / RNA 
24 splice variants 
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Protein 
374 amino acids SPOP comprises a N-term MATH 
domain (Meprin And TRAF Homology; substrate 
recognition and binding), a BTB/POZ domain 
(Bric-a-brac, Tramtrack and Broad complex/ Pox 
virus and Zinc finger; connects to the CUL3 - 
RBX1 (Cullin 3-RING box 1) scaffold protein), a 
3-box domain (facilitating CUL3 binding and 
resembling to F-/SOCS-boxes) and a C-terminal 
nuclear localization sequence. SPOP is a E3 
ubiquitin ligase adaptor protein that participates in 
the degradation of various substrates. AR (androgen 
receptor), DAXX, BMI1, BRMS1 and PDX1 are 
targets of SPOP. SPOP is critically involved in 
SETD2 (a tumor suppressor) stability. SPOP 
enables homology-directed DNA repair of double 
strand breaks, and mutant SPOP promotes genomic 
rearrangements within chromosomes. SPOP 
suppresses gastric tumorigenesis through inhibiting 
hedgehog/ GLI2 signaling pathway. SPOP is 
frequently mutated in prostate and endometrial 
cancers. TMPRSS2 - ERG fusions, frequently seen 
in prostate carcinoma, encode N-terminal-truncated 
ERG proteins that are resistant to the SPOP-
mediated degradation. Decreased expression of 
SPOP is associated with poor prognosis in glioma. 
On the other hand, SPOP is highly expressed in 
clear cell renal cell carcinoma (Zhuang et al., 2009; 
Mani, 2014; Zeng et al., 2014; Karnes et al., 2015; 
Ding et al., 2015; Rider and Cramer, 2015). 
References 
Aguilo F, Avagyan S, Labar A, Sevilla A, Lee DF, Kumar P, 
Lemischka IR, Zhou BY, Snoeck HW. Prdm16 is a 
physiologic regulator of hematopoietic stem cells. Blood. 
2011 May 12;117(19):5057-66 
An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X,  
Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling 
GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang 
Q, Zhang J, Cheville JC, Yan J, Sun Y, Huang H. 
Truncated ERG Oncoproteins from TMPRSS2-ERG 
Fusions Are Resistant to SPOP-Mediated Proteasome 
Degradation. Mol Cell. 2015 Sep 17;59(6):904-16 
Bjork BC, Turbe-Doan A, Prysak M, Herron BJ, Beier DR. 
Prdm16 is required for normal palatogenesis in mice. Hum 
Mol Genet. 2010 Mar 1;19(5):774-89 
Chi J, Cohen P. The Multifaceted Roles of PRDM16: 
Adipose Biology and Beyond. Trends Endocrinol Metab. 
2016 Jan;27(1):11-23 
Chuikov S, Levi BP, Smith ML, Morrison SJ. Prdm16 
promotes stem cell maintenance in multiple tissues, partly 
by regulating oxidative stress. Nat Cell Biol. 2010 
Oct;12(10):999-1006 
Ding D, Song T, Jun W, Tan Z, Fang J. Decreased 
expression of the SPOP gene is associated with poor 
prognosis in glioma. Int J Oncol. 2015 Jan;46(1):333-41 
Kajimura S, Seale P, Kubota K, Lunsford E, Frangioni JV, 
Gygi SP, Spiegelman BM. Initiation of myoblast to brown 
fat switch by a PRDM16-C/EBP-beta transcriptional 
complex. Nature. 2009 Aug 27;460(7259):1154-8 
Mani RS. The emerging role of speckle-type POZ protein 
(SPOP) in cancer development. Drug Discov Today. 2014 
Sep;19(9):1498-502 
Rider L, Cramer SD. SPOP the mutation. Elife. 2015 Oct 
27;4 
Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, 
Vegesna R, Kim H, Verhaak RG. The landscape and 
therapeutic relevance of cancer-associated transcript 
fusions. Oncogene. 2015 Sep 10;34(37):4845-54 
Zeng C, Wang Y, Lu Q, Chen J, Zhang J, Liu T, Lv N, Luo 
S. SPOP suppresses tumorigenesis by regulating 
Hedgehog/Gli2 signaling pathway in gastric cancer. J Exp 
Clin Cancer Res. 2014 Sep 11;33:75 
Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, 
Hammel M, Miller DJ, Walden H, Duda DM, Seyedin SN, 
Hoggard T, Harper JW, White KP, Schulman BA. 
Structures of SPOP-substrate complexes: insights into 
molecular architectures of BTB-Cul3 ubiquitin ligases. Mol 
Cell. 2009 Oct 9;36(1):39-50 
This article should be referenced as such: 
Nervous system: Astrocytoma with t(1;17)(p36;q21) 
SPOP/PRDM16. Nervous system: Astrocytoma with 
t(1;17)(p36;q21) SPOP/PRDM16. Atlas Genet Cytogenet 
Oncol Haematol. 2017; 21(12):470-471. 
